MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-19-2025
Vivos Therapeutics Gross Profit 2011-2026 | VVOS
Gross profit is a key indicator of how efficiently a company produces or sells its products. This metric helps assess a business’s ability to generate revenue at the initial stage, before accounting for all other expenses. Regular analysis of gross profit allows companies to respond in a timely manner to changes in cost of goods, pricing strategy, and market conditions.
Calculation formula:Importance for business:
Gross Profit = Revenue – Cost of Goods Sold (COGS)
Revenue — all cash inflows from the sale of goods or services.
Cost of Goods Sold — direct costs related to the production or acquisition of goods:
- Raw materials and supplies
- Wages of production personnel
- Depreciation of equipment
- Transportation and warehousing costs (if directly related to production)
- Assessing core business profitability
If gross profit is declining, it may indicate rising production costs or falling sales. - Financial planning
Gross profit is the basis for calculating other key metrics, such as operating and net profit. - Benchmarking against competitors
Gross profit analysis helps compare the efficiency of different companies within the same industry. - Insights into pricing effectiveness
If gross profit is low, the company may be pricing too low or failing to control costs effectively.
- Increase in raw material and supply costs
- Rising production expenses
- Price reductions due to competition
- Decrease in sales volume
- Currency exchange rate fluctuations (for imports/exports)
Gross profit is an important metric, but it does not provide a complete picture of a company’s financial health, as it does not account for administrative and selling expenses, taxes, debt burden, or depreciation.
Annual Gross Profit Vivos Therapeutics
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 9.02 M | 8.27 M | 10 M | 12.6 M | 10.4 M | 8.66 M | 2.71 M | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 12.6 M | 2.71 M | 8.81 M |
Quarterly Gross Profit Vivos Therapeutics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3.94 M | 2.11 M | 1.51 M | - | 2.33 M | 2.65 M | 1.94 M | - | 1.75 M | 2.1 M | 2.34 M | - | 2.5 M | 2.59 M | 2.37 M | - | 3.18 M | 3.62 M | 2.69 M | - | 2.58 M | 2.73 M | 2.42 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 3.94 M | 1.51 M | 2.52 M |
Gross Profit of other stocks in the Medical devices industry
| Issuer | Gross Profit | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
BioSig Technologies
BSGM
|
229 K | - | 37.08 % | $ 85.7 M |  USA |
 |
GenMark Diagnostics, Inc.
GNMK
|
67.9 M | - | - | $ 1.77 B | USA |
 |
Axonics Modulation Technologies
AXNX
|
198 M | - | - | $ 3.31 B | USA |
 |
Xtant Medical Holdings
XTNT
|
68.2 M | $ 0.55 | -2.31 % | $ 73.5 M | USA |
 |
Dynatronics Corporation
DYNT
|
6.01 M | - | 14.99 % | $ 929 K | USA |
 |
Aziyo Biologics
AZYO
|
6.6 M | - | 1.37 % | $ 20.5 M | USA |
 |
Acutus Medical
AFIB
|
-3.14 M | - | -26.83 % | $ 2.62 M | USA |
 |
Zimmer Biomet Holdings
ZBH
|
5.73 B | $ 88.57 | -0.65 % | $ 18 B | USA |
 |
Allied Healthcare Products
AHPI
|
443 K | - | 3.58 % | $ 2.21 M | USA |
 |
Obalon Therapeutics, Inc.
OBLN
|
584 K | - | -5.86 % | $ 30.6 M | USA |
 |
Alphatec Holdings
ATEC
|
532 M | $ 10.93 | -5.12 % | $ 1.64 B | USA |
 |
Conformis
CFMS
|
23.2 M | - | - | $ 16.4 M | USA |
 |
Accuray Incorporated
ARAY
|
147 M | $ 0.4 | 4.21 % | $ 41.1 M | USA |
 |
Cardiovascular Systems
CSII
|
173 M | - | 0.15 % | $ 844 M | USA |
 |
Second Sight Medical Products
EYES
|
500 K | - | -0.97 % | $ 54.4 M | USA |
 |
Apollo Endosurgery
APEN
|
42.4 M | - | - | $ 475 M | USA |
 |
Avinger
AVGR
|
2 M | - | -20.74 % | $ 369 K | USA |
 |
CryoLife, Inc.
CRY
|
168 M | - | -4.14 % | $ 702 M | USA |
 |
CONMED Corporation
CNMD
|
750 M | $ 34.58 | -5.62 % | $ 1.07 B | USA |
 |
Hancock Jaffe Laboratories, Inc.
HJLI
|
4.25 K | - | -1.98 % | $ 98.3 M | USA |
 |
Itamar Medical Ltd.
ITMR
|
28.7 M | - | 0.03 % | $ 1.58 B |  Israel |
 |
NanoVibronix
NAOV
|
1.51 M | - | - | $ 1.08 M | USA |
 |
Misonix, Inc.
MSON
|
43.7 M | - | - | $ 462 M | USA |
 |
Neovasc
NVCN
|
1.99 M | - | - | $ 111 M |  Canada |
 |
Intersect ENT, Inc.
XENT
|
50.2 M | - | - | $ 955 M | USA |
 |
Cytosorbents Corporation
CTSO
|
25.1 M | $ 0.59 | -1.18 % | $ 32.1 M | USA |
 |
Aethlon Medical
AEMD
|
1.36 M | $ 2.15 | -5.29 % | $ 3.36 M | USA |
 |
Edwards Lifesciences Corporation
EW
|
4.73 B | $ 79.34 | -3.36 % | $ 46.4 B | USA |
 |
BIOLASE
BIOL
|
16.7 M | - | -13.19 % | $ 166 K | USA |
 |
AdaptHealth Corp.
AHCO
|
89.3 M | $ 11.2 | -1.84 % | $ 1.51 B | USA |
 |
OrthoPediatrics Corp.
KIDS
|
173 M | $ 15.52 | -5.08 % | $ 364 M | USA |
 |
Invacare Corporation
IVC
|
48.3 M | - | - | $ 24.7 M | USA |
 |
Ra Medical Systems
RMED
|
-147 K | - | 10.0 % | $ 610 K | USA |
 |
Myomo
MYO
|
26.9 M | $ 0.7 | 2.32 % | $ 29.3 M | USA |
 |
Penumbra
PEN
|
942 M | $ 335.1 | -0.39 % | $ 13 B | USA |
 |
Inspire Medical Systems
INSP
|
779 M | $ 50.13 | -0.63 % | $ 1.47 B | USA |
 |
Pulmonx Corporation
LUNG
|
67.1 M | $ 1.17 | -5.65 % | $ 47.6 M | USA |
 |
Cutera
CUTR
|
-12.7 M | - | -10.19 % | $ 1.99 M | USA |
 |
Eargo
EAR
|
14.3 M | - | - | $ 10.2 M | USA |
 |
NuVasive
NUVA
|
865 M | - | - | $ 2.07 B | USA |
 |
Nevro Corp.
NVRO
|
270 M | - | - | $ 217 M | USA |
 |
Surgalign Holdings
SRGA
|
40.3 M | - | -32.98 % | $ 1.68 M | USA |
 |
STRATA Skin Sciences
SSKN
|
21.8 M | - | - | $ 6.6 M | USA |
 |
GBS
GBS
|
1.25 M | - | -0.57 % | $ 7.12 M | USA |
 |
AVITA Medical
RCEL
|
58.8 M | $ 3.82 | -1.04 % | $ 106 M |  Australia |
 |
AxoGen
AXGN
|
167 M | $ 31.28 | -3.01 % | $ 1.44 B | USA |
 |
Delcath Systems
DCTH
|
73.4 M | $ 8.97 | -1.75 % | $ 321 M | USA |